Ozmosi | Foretinib Drug Profile
Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

Foretinib

Alternative Names: foretinib, xl880, gsk1363089
Clinical Status: Inactive
Latest Update: 2024-04-15
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: RTK Inhibitor, C-Met Inhibitor, VEGFR Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: GSK
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 2: Gastrointestinal Cancer|Non-Small-Cell Lung Cancer|Head and Neck Cancer|Squamous Cell Carcinoma|Lung Cancer|Renal Cell Carcinoma|Breast Cancer

Phase 1: Oncology Solid Tumor Unspecified|Hepatocellular Carcinoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated
NCT00920192

P1

Completed

Hepatocellular Carcinoma

2012-03-07

2019-03-18

Treatments
MET111516

P1

Completed

Oncology Solid Tumor Unspecified

2009-06-24

2019-03-18

Treatments
MET111648

P1

Completed

Oncology Solid Tumor Unspecified

2009-05-02

2019-03-18

Treatments
MET111647

P1

Completed

Oncology Solid Tumor Unspecified

2008-05-13

2019-03-18

Treatments
IND197

P2

Completed

Breast Cancer

2014-12-14

2023-08-05

Primary Endpoints|Start Date|Treatments
I198

P2

Completed

Breast Cancer

2014-05-14

2023-08-05

Primary Endpoints|Start Date|Treatments
NCT02034097

P2

Withdrawn

Non-Small-Cell Lung Cancer

2014-04-01

2019-03-20

Treatments
I196

P2

Completed

Lung Cancer

2014-03-21

2023-08-05

Primary Endpoints|Start Date
MET111644

P2

Completed

Renal Cell Carcinoma

2010-08-18

2019-03-18

Treatments
MET111643

P2

Completed

Gastrointestinal Cancer

2009-11-01

2019-03-18

Treatments
MET111646

P2

Completed

Head and Neck Cancer|Squamous Cell Carcinoma

2009-05-02

2019-03-18

Treatments

Recent News Events

Date

Type

Title

04/15/2024

PubMed

 The HGF/Met Receptor Mediates Cytotoxic Effect of Bacterial Cyclodipeptides in Human Cervical Cancer Cells.

03/11/2024

PubMed

 Design, synthesis, and biological evaluation of new biaryl derivatives of cycloalkyl diacetamide bearing chalcone moiety as type II c-MET kinase inhibitors.

03/01/2024

PubMed

 Foretinib, a c-MET receptor tyrosine kinase inhibitor, tackles multidrug resistance in cancer cells by inhibiting ABCB1 and ABCG2 transporters.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions